TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00717145
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one risedronate 20 mg DR tablet
Study: NCT00717145
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One risedronate 20 mg DR tablet
Study: NCT00717145
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One risedronate 35 mg DR tablet
Study: NCT00717145
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One risedronate 35 mg IR tablet
Study: NCT00459745
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00957411
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04275245
Drug: Meplazumab for Injection
Normalized name: mepolizumab Injection
DrugBank: Meplazumab (DB16465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized MAb against CD147
Study: NCT00930098
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03280147
Drug: 14-day course of antibiotics
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned.
Study: NCT00440921
Drug: Single donor Allogenous Fibrin Sealant
Normalized name: thrombin
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00867308
Drug: Lenalidomide 50 mg
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00867308
Drug: Lenalidomide 15 mg
Normalized name: lenalidomide 15 MG
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02731378
Drug: Erythropoietins (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
Study: NCT02731378
Drug: Erythropoietins (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
Study: NCT04512963
Drug: Progerinin
Normalized name: Progerinin
DrugBank: Progerinin (DB17634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/g nano-suspension for oral use
Study: NCT03194009
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
Study: NCT00291369
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00291369
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00291369
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00311688
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological response modifier in liquid form; dosage of drug will vary by study
Study: NCT02292459
Drug: Polyethylene Glycol 3350 Powder for Solution (PEG 3350)
Normalized name: polyethylene glycol 3350 Powder for Oral Solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02292459
Drug: Polyethylene Glycol 4000 Powder for Solution (PEG 4000)
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02338713
Drug: Noncarbonated Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncarbonated water 200 mL
Study: NCT00099164
Drug: 17 alpha-hydroxyprogesterone caproate (17P)
Normalized name: 17-alpha-hydroxyprogesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
Study: NCT02735980
Drug: Prexasertib
Normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02302846
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
Study: NCT00369915
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02642718
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
Study: NCT00386282
Drug: mifepristone-misoprostol treatment
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
Study: NCT00999401
Drug: sapacitabine and seliciclib
Normalized name: Capecitabine
DrugBank: Seliciclib (DB06195)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sequential or concomitant administration of sapacitabine and seliciclib
Study: NCT01774877
Drug: leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
Study: NCT00082875
Drug: cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02644395
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug
Study: NCT00804934
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5mg Lucentis every four months
Study: NCT00244998
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IM
Study: NCT02037815
Drug: 20% mannitol solution, 125 ml, IV infusion in 15 min
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02037815
Drug: 3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01936363
Drug: Pimasertib once daily
Normalized name: gabapentin
DrugBank: Pimasertib (DB14904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Study: NCT01936363
Drug: Pimasertib placebo
DrugBank: Pimasertib (DB14904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Study: NCT01936363
Drug: Pimasertib twice daily
Normalized name: clindamycin
DrugBank: Pimasertib (DB14904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Study: NCT01301261
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex 2 mg/kg when a two count of train of four appears
Study: NCT01301261
Drug: Sugammadex 4 mg/kg
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
Study: NCT01301261
Drug: Sugammadex 16mg/kg
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
Study: NCT00275171
Drug: Recombinant human thyrotropin (Thyrogen)
Normalized name: Recombinant thyrotropin alfa
DrugBank: Thyrotropin (DB15263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg rhTSH administered intramuscularly
Study: NCT04281082
Drug: ursofalk
Normalized name: Ursofalk
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
Study: NCT00115778
Drug: IVIG
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
Study: NCT01373697
Drug: Profenid
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
Study: NCT03967288
Drug: Chloroprocaine Injection [Clorotekal]
Normalized name: chloroprocaine Injection [Clorotekal]
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
Study: NCT03967288
Drug: Bupivacaine Hydrochloride 0.75% Injection Solution
Normalized name: Bupivacaine Hydrochloride 0.75% Injection Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
Study: NCT04653831
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Pirfenidone as mentioned in the experimental arm description.
Study: NCT00099086
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Study: NCT00099086
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
Study: NCT04152681
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
Study: NCT00458003
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
Study: NCT00458003
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
Study: NCT02016443
Drug: Tizanidine
Normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
Study: NCT03920475
Drug: Sertraline or venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
Study: NCT02762084
Drug: Patidegib
Normalized name: Patidegib
DrugBank: Patidegib (DB12655)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00614874
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg, 4mg, 8mg
Study: NCT01001910
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01001910
Drug: Pemetrexed Disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00078013
Drug: MCC-135
Normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03276598
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for four weeks. Dose: 5 mg o.d.
Study: NCT03276598
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment for four weeks. Dose: 5 mg o.d.
Study: NCT03276598
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for four weeks. Dose: 25 mg o.d.
Study: NCT03276598
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for four weeks. Dose: 50 mg o.d.
Study: NCT02898454
Drug: Dupilumab SAR231893 (REGN668)
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT01963702
Drug: Docetaxol
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01963702
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01139996
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
Study: NCT00511810
Drug: Low Dose Fish Oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
Study: NCT00511810
Drug: High Dose Fish Oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
Study: NCT01753882
Drug: Lexapro
Normalized name: Lexapro
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Agent + training vs Placebo + training
Study: NCT02998255
Drug: Single dose of 2L PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
Study: NCT03509168
Drug: Misoprostol Pfizer Brand
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
Study: NCT00676403
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study: NCT00676403
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study: NCT00676403
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study: NCT00676403
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study: NCT00676403
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study: NCT02307227
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02307227
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02307227
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02307227
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01831869
Drug: L-thyroxine
Normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00532545
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide 20 micrograms/daily subcutaneously
Study: NCT03164694
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib was given 850 mg per day orally.
Study: NCT03164694
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pemetrexed (500 mg/m2)
Study: NCT03164694
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin (AUC =5)
Study: NCT02634073
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
Study: NCT00379145
Drug: trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00972959
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
Study: NCT00558922
Drug: AEG35156
Normalized name: AEG35156
DrugBank: AEG35156 (DB06184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
Study: NCT03002220
Drug: radium-223
Normalized name: Radium-223
DrugBank: Radium Ra-223 (DB12813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 at a dose of 55 kBq
Study: NCT03360734
Drug: First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)
DrugBank: Tomuzotuximab (DB15178)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
Study: NCT00491166
Drug: Bromfenac ophthalmic solution
Normalized name: bromfenac Ophthalmic Solution
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127686
Drug: Buckwheat Honey
DrugBank: Buckwheat (DB10512)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00427505
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03704623
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1g IV
Study: NCT03704623
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg IV
Study: NCT03149809
Drug: solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
Study: NCT00972959
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
Study: NCT02048722
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00514618
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
Study: NCT01339039
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.